Newsroom All the latest news from the Pierre Fabre Group Page inner navigation PRESS RELEASES PRESS AREA NEWS PUBLICATIONS TWITTER Press releases Filter Year Year202520242023202220212020 Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Écrit le Min Max Appliquer Press release Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology 18 November 2021 Press release Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED 15 November 2021 Press release Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre 7 October 2021 Load more Presse area Are you a journalist? Find all the press releases of the Pierre Fabre group. Join us News Filter Year Year202520242023202220212020 Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Tags (field_news_tags) - Any -#CRCawarenessAcneCastres OlympiqueSeborrheic dermatitisDuoDayE-SANTÉEngagementHappy New YearKnow Your LemonsLittle Big DreamsPierre Fabre expertiseInternational Men's Day#OurBreastJourneyCOLLECTION PIERRE FABREConsortiumSustainable developmentDIGITALEADVESMOThe Gustave Roussy PrizeLettre OuverteLymphomaMedicalInnovationMedicalScienceLiaisonMelanomaMSLPink OctoberOncologyANNUAL REPORTStudyEventsPierre Fabre FoundationInnovationNominationsPartnershipsAwardsStrategyTalents Écrit le Min Max Appliquer Strategy The Pierre Fabre Group unveils its Purpose 17 February 2020 Innovation Pierre Fabre and startups CareOS and Revieve are launching a connected mirror for skin diagnosis 17 January 2020 Publications Aucun résultat Follow our live news Social media type (field_social_media_type) FacebookInstagramTwitterLinkedin Appliquer No post to display
Press release Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology 18 November 2021
Press release Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED 15 November 2021
Press release Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre 7 October 2021
Innovation Pierre Fabre and startups CareOS and Revieve are launching a connected mirror for skin diagnosis 17 January 2020
